Edison Healthcare Insight report - August 2015. Prima Biomed is mentioned on page 42 of 58...
http://www.google.com.au/url?sa=t&rct=j&q=&esrc=s&source=web&cd=9&ved=0CE0QFjAIahUKEwiPkrahr7nHAhUkIaYKHQ2IBo8&url=http://www.edisoninvestmentresearch.com/?ACT=19&ID=14694&dir=monthlybooks&field=19&ei=MK3WVY-6L6TCmAWNkJr4CA&usg=AFQjCNGY7Ak6ocHa4byCxfoWeWUy25uKcA&sig2=ABboT3KbJ1S1lAlITj3Gbg
Immunotherapies are among the most promising class of products for cancer andenhanced and more efficient production platform.
autoimmune diseases. The LAG-3 products are potentially first-in-class, each with distinct
mechanisms and applications. CVac is a similar treatment to Dendreon's Provenge, with an
Prima Biomed - Undervalued Biotech!, page-3
-
- There are more pages in this discussion • 21 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
31.5¢ |
Change
-0.005(1.56%) |
Mkt cap ! $457.5M | |||
| Open | High | Low | Value | Volume |
| 31.5¢ | 31.8¢ | 30.5¢ | $200.0K | 641.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 9 | 115661 | 31.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 32.0¢ | 22602 | 1 |
View Market Depth
| Last trade - 16.10pm 12/08/2024 (20 minute delay) ? |
| IMM (ASX) Chart |